Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Denver, Colorado 80206


Purpose:

The purpose of this study is to determine whether or not adding Raltegravir to a fully suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic inflammation and increase the t-lymphocyte memory cell pool.


Criteria:

Inclusion Criteria: 1. At least 18 years of age 2. HIV-positive by Western blot or viral load 3. Viral load < 400 copies/ml 4. CD4+ T-lymphocyte count less than 350 cells/mm3 or change in CD4+ T-lymphocyte count < 100 cells/mm3 for at least one year on stable HAART with viral load < 400 copies/ml for the same period of time Exclusion Criteria: 1. CD4+ T-lymphocyte count greater than or equal to 350 cells/mm3 or rise in CD4+ T-lymphocyte count greater than or equal to 100 cells/mm3 within one year of study entry 2. Viral load > 400 copies/ml 3. Allergy or resistance to raltegravir


NCT ID:

NCT00738569


Primary Contact:

Principal Investigator
Kenneth A Lichtenstein, MD
National Jewish Health


Backup Contact:

N/A


Location Contact:

Denver, Colorado 80206
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.